Comparison of the efficacy of ceftibuten and norfloxacin in the treatment of acute gastrointestinal infection in children

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 30, Issue 4, 1999, Pages 764-769

  Moolasart, Pikul ^a   Eampokalap, Boonchuay ^a   Ratanasrithong, Monthaswas ^a  

^a Bamrasnaradura Infectious Disease Institute   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFTIBUTEN; CEPHALOSPORIN DERIVATIVE; NORFLOXACIN;

ACUTE DISEASE; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; INFANT; MALE; PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SALMONELLOSIS; SHIGELLOSIS;

ACUTE DISEASE; ANTI-INFECTIVE AGENTS; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; DIARRHEA; DRUG RESISTANCE, MICROBIAL; DYSENTERY, BACILLARY; FEMALE; HUMANS; INFANT; MALE; NORFLOXACIN; PROSPECTIVE STUDIES; SALMONELLA INFECTIONS;

EID: 0033287230     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Barr WH, Affrime M, Lin CC, Batra V. Pharmacokinetics of ceftibuten in children. Pediatr Infect Dis 1993; 12: S55-63.
2. Bauernfeind A. Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany. Diagn Microbiol Infect Dis 1991; 14: 63-74.
3. Berkovitch M, Pastuszak A, Gazarian M, Lewis M, Koren G. Safety of the new quinolones in pregnancy. Obstet Gynecol 1994; 4: 535-8.
4. Galova K, Sufliarska S, Kukova Z, et al. Multicenter randomized study of two once daily regimens in the initial management of community-acquired respiratory tract infections in 163 children: azithromycin versus cefitibuten. Chemotherapy 1996; 42: 231-4.
5. Guay DR. Ceftibuten: a new expanded-spectrum oral cephalosporin. Am Pharmacotherapy 1997; 31: 1002-33.
6. Helwig H. Contemporary issues in the management of pediatric infections. Pediatr Infect Dis 1997; 16: S39-42.
7. Jones RN, Barry AL. Ceftibuten (7432-S, Sch39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability, and broth microdilution quality-control guidelines. Eur J Clin Microbiol Infect Dis 1988; 7: 802-7.
8. Jones RN. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features. Pediatr Infect Dis J 1993; 12: S37-44.
9. Kabir I, Butler T, Khanam A. Comparative efficacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in a placebo-controlled trial. Antimicrob Agents Chemother 1986; 29: 645-8.
10. th ed. Washington, DC: Am Soc Microbiol 1985: 263-77.
11. Levine WC, Buehler JW, Bean NH, et al. Epidemiology of non-typhoidal Salmonella bacteremia during the human immunodeficiency virus epidemic. J Infect Dis 1991; 164: 81-7.
12. Ling J, Kam KM, Lam AW, French GL. Susceptibility of Hong Kong isolates of multiply resistant Shigella spp to 25 antimicrobial agents, including ampicillin plus sulbactam and new 4-quinolones. Antimicrob Agents Chemother 1988; 32: 20-3.
13. Maiorini E, Lopez EL, Morrow AL, et al. Multiple resistant nontyphoidal Salmonella gastroenteritis in children. Pediatr Infect Dis J 1993; 12: 139-44.
14. Mandel EM, Casselbrant ML, Kurs Lasky M, Bluestone CD. Efficacy of ceftibuten compared with amoxicillin for otitis media with effusion in infants and children. Pediatr Infect Dis 1996; 15: 409-14.
15. Medeiros AA, Crellin J. Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: effect of large inocula. Pediatr Infect Dis 1997; 16: S49-55.
16. Moolasart P, Eampokalap B. Shigellosis in Thai people. JAMA SEA 1994; 10: 9-10.
17. Moolasart P, Sangsujja J, Eampokalap B, Ratanasrithong M, Likanonsakul S. Nontyphoidal Salmonella diarrhea in Thai children: a study at Bamrasnaradura Hospital, Nonthaburi, Thailand. J Med Assoc Thai 1997; 80: 613-8.
18. Moolasart P, Eampokalap B, Supaswadikul S. Comparison of the efficacy of tetracycline and norfloxacin in the treatment of acute severe watery diarrhea. Southeast Asian J Trop Med Public Health 1998; 29: 108-11.
19. National Committee for Clinical Laboratory Standards. Performance standard for antimicrobial disk susceptibility test. 6th ed. Approved standard. NCCLS document M2-A6. NCCLS, Wayne, Pennsylvania. 1997.
20. Owens RC Jr, Nightingale CH, Nicolau DP. Ceftibuten: an overview. Pharmacotherapy 1997; 17: 707-20.
21. Prado D, Lopez E, Lui H, et al. Ceftibuten and trimethoprim sulfamethoxazole for treatment of Shigella and enteroinvasive Escherichia coli disease. Pediatr Infect Dis 1992; 11: 644-7.
22. Pichichero ME. Empiric antibiotic selection criteria for respiratory infections in pediatric practice. Pediatr Infect Dis 1997; 16 (3 suppl): S60-4.
23. Reidenberg BE. Worldwide safety experience with ceftibuten pediatric suspension. Pediatr Infect Dis 1995; 14 (suppl): S130-3.
24. Richards L, Claeson M, Pierce NF. Management of acute diarrhea in children: lessons learned. Pediatr Infect Dis 1993; 12: 5-9.
25. Sirivichayakul C, Thisyakorn U. Severe shigellosis in childhood. Southeast Asian J Trop Med Public Health 1998; 29: 555-9.
26. Stahlmann R. Safety profile of the quinolones. J Antimicrob Chemother 1990; 26 (suppl D): 31-44.
27. Varsano I, Eidlitz-Marcus T, Nussinovitch M, Elian I. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. J Pediatr 1991; 118: 627-32.
28. Verbist L, Jacobs J, Hens K. Comparative antimicrobial activity of ceftibuten against multiple-resistant microorganisms from Belgium. Diagn Microbiol Infect Dis 1991; 14: 53-61.
29. Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol 1996; 4: 277-84.
30. World Health Organization. A manual for the treatment of acute diarrhea: medicines. Bull WHO 1990; 80: 13-4.